Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target
Open Access
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (9), 4028-4033
- https://doi.org/10.1158/0008-5472.can-07-0345
Abstract
Protein kinases are central targets for drug-based cancer treatment. To avoid functional impairment, the cell develops mechanisms of drug resistance, primarily based on adaptive mutations. Redesigning a drug to target a drug-resistant mutant kinase constitutes a therapeutic challenge. We approach the problem by redesigning the anticancer drug imatinib guided by local changes in interfacial de-wetting propensities of the C-Kit kinase target introduced by an imatinib-resistant mutation. The ligand is redesigned by sculpting the shifting hydration patterns of the target. The association with the modified ligand overcomes the mutation-driven destabilization of the induced fit. Consequently, the redesigned drug inhibits both mutant and wild-type kinase. The modeling effort is validated through molecular dynamics, test tube kinetic assays of downstream phosphorylation activity, high-throughput bacteriophage-display kinase screening, cellular proliferation assays, and cellular immunoblots. The inhibitor redesign reported delineates a molecular engineering paradigm to impair routes for drug resistance. [Cancer Res 2007;67(9):4028–33]Keywords
Other Versions
This publication has 21 references indexed in Scilit:
- Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisBlood, 2006
- Circumventing Resistance to Kinase-Inhibitor TherapyThe New England Journal of Medicine, 2006
- Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human MalignanciesCancer Research, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970Blood, 2004
- Keeping dry and crossing membranesNature Biotechnology, 2004
- Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine KinasePublished by Elsevier BV ,2004
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.JCI Insight, 1993
- Establishment of an immature mast cell line from a patient with mast cell leukemiaLeukemia Research, 1988